About

About WuXi AppTec As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that 'every drug can be made and every disease can be treated.' WuXi AppTec offers a comprehensive platform of targeted oncology models and translational services to support cancer drug development teams within the global pharmaceutical and healthcare industry. Our services include CAR-T cell therapy, antibody-drug conjugates, CRISPR-mediated target validation, drug-resistant CDX/PDX tumor models, and discovery/clinical biomarker services.